Friday, November 13, 2026
ExploreSearch
Via News

financial-regulation

2 articles

U.S. Ratings Firm's Dual Role Echoes Global Conflict-of-Interest Debate

U.S. Ratings Firm's Dual Role Echoes Global Conflict-of-Interest Debate

The Oasis Group rates wealth management and estate planning vendors while selling consulting services to the same market — a structural conflict regulators worldwide have scrutinized since 2008. The firm's 2026 Peaks for Estate Planning Platforms report is widely cited in fintech circles, raising questions about independence that remain publicly unanswered. No specific incident has been identified, but analysts rate the governance risk as major severity.

Via News Editorial Team•
Texas CEO Nate Paul Convicted of Wire Fraud in $172M Real Estate Scheme

Texas CEO Nate Paul Convicted of Wire Fraud in $172M Real Estate Scheme

Nate Paul, CEO of Austin-based World Class Capital Group, faces mandatory restitution and asset forfeiture after conviction for wire fraud involving falsified loan applications. Federal prosecutors pursue recovery of losses from commercial real estate financing fraud that exploited US banking systems. The case reflects intensified global enforcement against real estate loan fraud, with similar prosecutions rising in UK, Australia, and Canada.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com